Last reviewed · How we verify
NCT04341480
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19
trial testing Chemotherapy in Gynecological Cancer in 305 participants. Status unknown.
10 December 2022
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 305 |
| Start date | 1 July 2020 |
| Primary completion | 10 December 2022 |
| Estimated completion | 10 January 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chemotherapy (chemotherapy) — full drug profile →
Conditions studied
- Gynecological Cancer — all drugs for Gynecological Cancer →
Sponsor
Tongji Hospital
Who can join
Adults 18 to 80, female only, with Gynecological Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) emerged at December 2019 in Wuhan, China, and soon caused a large global outbreak. The delayed treatment for many chronic diseases, due to the concern of SARS-CoV-2 infection, is an increasing serious problem. Here the investigators investigate the safety of chemotherapy for patients with gynecological malignancy in Wuhan, the center of high-risk regions of COVID-19.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237
Verify or expand the search:
- PubMed search for NCT04341480
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chemotherapy
Trials testing the same drug.
- NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting
Other recruiting trials for Gynecological Cancer
Currently open trials in the same condition.
- NCT06780813 — Supplemental High Flow Oxygen to Reduce Infections in Obese Gynecological Cancer Patients · NA · recruiting
- NCT06039306 — Perioperative Immunonutrition Under Enhanced Recovery After Surgery · NA · recruiting
- NCT06676267 — Laparoscopic Surgical Systems for Gynecological and Remote Surgical Treatment. · NA · recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04341480 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 7 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04341480.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing